Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 2

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
Stock-based compensation— — 30,571 — — 30,571 Net loss— — — (34,358)— (34,358)Other comprehensive income— — — — 126 126 Balance as of March 31, 2025123,133,750 $2 $2,208,665 $(1,501,405)$(367)$706,895 

Common StockAdditional Paid-inCapitalAccumulatedDeficitAccumulatedOther ComprehensiveLossTotalStockholders’EquitySharesAmountBalance as of December 31, 2023119,095,362 $2 $2,025,890 $(1,284,420)$(429)$741,043 Issuance of Class A common stock related to equity awards605,487 — 1,638 — — 1,638 Stock-based compensation— — 36,129 — — 36,129 Net loss— — — (59,949)— (59,949)Other comprehensive loss— — — — (27)(27)Balance as of March 31, 2024119,700,849 $2 $2,063,657 $(1,344,369)$(456)$718,834 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

10x Genomics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Three Months Ended March 31,20252024Operating activities:Net loss$(34,358)$(59,949)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense31,076 36,129 Depreciation and amortization8,022 9,194 Amortization of right-of-use assets1,792 2,300 Lease and asset impairment charges114 2,454 Other(575)444 Changes in operating assets and liabilities:Accounts receivable35,325 23,516 Inventory8,058 (9,937)Prepaid expenses and other current assets(5,530)(2,029)Other noncurrent assets2,314 216 Accounts payable(2,547)4,583 Accrued compensation and other related benefits(11,745)(9,